대한신장학회

논문분류	춘계학술대회 초록집
제목	Unwrapping the GIFT Panel: Technical Feasibility and Preliminary Signals of a Novel Multi-Biomarker Panel for DKD Progression in Type 2 Diabetes Mellitus
저자	Priya Rani
출판정보	2026; 2026(1):
키워드	Diabetic Kidney Disease , Prognostic Potential, Urinary Biomarker, Rapid Progression, Diabetic Nephropathy
초록	Objectives: Albuminuria and eGFR detect DKD progression only after irreversible structural injury, leaving a critical early intervention window unaddressed. DKD is mechanistically heterogeneous simultaneously engaging glomerular injury, tubular damage, and inflammatory-fibrotic cascades yet no validated multi-pathway urinary biomarker tool exists for early-stage risk stratification. We introduce the GIFT (Glomerular-Inflammatory-Fibrotic-Tubular marker) panel comprising CTGF, Cystatin C, KIM-1, NGAL, TNF-α, MCP-1, and TGF-β, and evaluate its analytical feasibility and prognostic signals across CKD stages 1–3b in Type 2 Diabetes Mellitus. Methods: This prospective observational pilot study (November 2024–March 2025) enrolled 40 adults with T2DM-associated CKD at KMC Manipal, India. Baseline biospecimens were quantified by seven-plex ELISA validated by four-parameter logistic (4PL) regression with inverse prediction. Rapid progression was defined as an eGFR decline of ≥5 mL/min/1.73 m²/year (CKD-EPI) over 12 months of follow-up. Discrimination was assessed by ROC-AUC analysis; leave-one-out cross-validation (LOOCV) estimated optimism-adjusted panel performance. Subgroup analyses were stratified by albuminuria category. Results: Thirty-nine patients were evaluable; 12 (30.8%) were rapid progressors. All 7 4PL assays converged with validated inverse-prediction accuracy. Individually, CTGF demonstrated the strongest discrimination (AUC 0.670; 95% CI: 0.473–0.866; sensitivity 75%) and approached independent significance on multivariate analysis (p=0.064). The apparent combined panel AUC of 0.716 collapsed to 0.370 under LOOCV (optimism=0.346), confirming overfitting at this event-to-predictor ratio and the necessity of the planned whole cohort (n=145). Albuminuria-stratified analyses revealed distinct stage-specific signals: CTGF achieved an AUC of 0.750 in the microalbuminuria subgroup, while Cystatin C reached an AUC of 0.756 in macroalbuminuric patients. Conclusion: The GIFT panel establishes robust analytical feasibility and generates biologically coherent, albuminuria-contextualised prognostic signals consistent with DKD's mechanistic heterogeneity. Definitive panel-level inference awaits the fully powered validation cohort.
원문(PDF)	PDF 원문보기

간행물 검색

대한신장학회 회원관리 규정